SB-728-T

BIOLOGICAL4 trials

Sponsors

Sangamo Therapeutics, University of Cincinnati

Conditions

HIVHIV InfectionHIV Infections

Phase 1

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

CompletedNCT01044654

Sangamo TherapeuticsHIV Infection, HIV Infections

Start: 2009-12-31End: 2014-12-31Updated: 2015-03-13

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

CompletedNCT01252641

Sangamo TherapeuticsHIV, HIV Infection

Start: 2010-11-30End: 2015-05-31Updated: 2019-09-20

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

CompletedNCT01543152

Sangamo TherapeuticsHIV

Start: 2011-12-31End: 2017-07-07Updated: 2021-05-24

CCR5-modified CD4+ T Cells for HIV Infection

CompletedNCT03666871

University of CincinnatiHIV Infections

Start: 2019-06-12End: 2024-02-28Updated: 2024-05-21

Related Papers

Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells

Molecular Therapy — Methods & Clinical Development2016-01-01108 citations